CureVac to Present New Findings at SITC Annual Meeting

TÜBINGEN, Germany/BOSTON, USA – October 28, 2024 – CureVac, a biopharmaceutical company focusing on mRNA-based therapies, will present at the Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston from November 8-10. The company will share extended preliminary results on its CVGBM cancer vaccine from a Phase 1 study in glioblastoma patients. This follows presentations at the European Society for Medical Oncology Congress, showing promising T-cell responses.

The meeting includes sessions on the impact of mRNA vaccination on T-cell therapy in solid tumors. Key presenters from CureVac include Dr. Sven Koch, Dr. Johannes Lutz, and Dr. Katka Franke across various study areas, emphasizing CureVac's ongoing commitment to advancing mRNA technology in cancer treatment.